Psychotic symptoms are common in people with PD and are associated with poor prognosis, such as greater physical disability, cognitive and emotional impairment, caregiver distress, nursing home placement and death.
The FDA granted priority review status to Enhertu (DS-8201) for the treatment of patients with HR-positive, low HER2-expressing breast cancer, and Enhertu has enabled these patients to remain disease-free for an average of 10.1 months, with an average overall survival time of nearly two years. A decision on approval is expected to be made in the fourth quarter of this year.
